ArticlePharmacoEconomics2013

A comment on Boyers et al.: "eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal".

Rachel Allen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.